EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhanced Anti-Tumor Response Elicited by a Novel Oncolytic Pseudorabies Virus Engineered with a PD-L1 Inhibitor

Guangtao Xiang iD, Mengdong Wang, Pu Wang iD, Rifei Li, Chao Gao, Yue Li, Xinxin Liang, Yun Liu, Aotian Xu, Jun Tang iD

Viruses · 2024

DOI: 10.3390/v16081228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Guangtao Xiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Veterinary Medicine, China Agricultural University, Beijing 100193, China. Hauptthemen laut MEDLINE: Oncolytic Viruses, Herpesvirus 1, Suid, Oncolytic Virotherapy, Melanoma, Experimental. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cytovaxis Biotechnologies Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncolytic viruses combined with immunotherapy offer significant potential in tumor therapy. In this study, we engineered a further attenuated pseudorabies virus (PRV) vaccine strain that incorporates a PD-L1 inhibitor and demonstrated its promise as an oncolytic virus in tumor therapy. We first showed that the naturally attenuated PRV vaccine strain Bartha can efficiently infect tumor cells from multiple species, including humans, mice, and dogs in vitro. We then evaluated the safety and anti-tumor efficacy of this vaccine strain and its different single-gene deletion mutants using the B16-F10 melanoma mouse model. The TK deletion strain emerged as the optimal vector, and we inserted a PD-L1 inhibitor (iPD-L1) into it using CRISPR/Cas9 technology. Compared with the control, the recombinant PRV (rPRV-iPD-L1) exhibited more dramatic anti-tumor effects in the B16-F10 melanoma mouse model. Our study suggests that PRV can be developed not only as an oncolytic virus but also a powerful vector for expressing foreign genes to modulate the tumor microenvironment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirusesHerpesvirus 1, SuidOncolytic VirotherapyMelanoma, ExperimentalB7-H1 AntigenAnimalsMiceHumansCell Line, TumorMice, Inbred C57BLFemaleDogsImmune Checkpoint InhibitorsGenetic VectorsImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

PRViPD-L1mouse melanomaoncolytic virus

Substanzen

B7-H1 AntigenImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • College of Veterinary Medicine, China Agricultural University, Beijing 100193, China.
  • Cytovaxis Biotechnologies Inc., Guangzhou 510760, China.

ORCID-Profile: Guangtao Xiang, Pu Wang, Jun Tang

Förderung

  • Cytovaxis Biotechnologies Inc

Zitieren

APA

Xiang, G., Wang, M., Wang, P., Li, R., Gao, C., Li, Y., Liang, X., Liu, Y., Xu, A., & Tang, J. (2024). Enhanced Anti-Tumor Response Elicited by a Novel Oncolytic Pseudorabies Virus Engineered with a PD-L1 Inhibitor. Viruses. https://doi.org/10.3390/v16081228

Vancouver

Xiang G, Wang M, Wang P, Li R, Gao C, Li Y, et al. Enhanced Anti-Tumor Response Elicited by a Novel Oncolytic Pseudorabies Virus Engineered with a PD-L1 Inhibitor. Viruses. 2024. doi:10.3390/v16081228

BibTeX
@article{Xiang2024,
  author = {Xiang, Guangtao and Wang, Mengdong and Wang, Pu and Li, Rifei and Gao, Chao and Li, Yue and Liang, Xinxin and Liu, Yun and Xu, Aotian and Tang, Jun},
  title = {Enhanced Anti-Tumor Response Elicited by a Novel Oncolytic Pseudorabies Virus Engineered with a PD-L1 Inhibitor},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16081228}
}
Kostenlos starten →